Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $30,073 | $37,433 |
| General and administrative | 11,294 | 9,975 |
| Total operating expenses | 41,367 | 47,408 |
| Loss from operations | (41,367) | (47,408) |
| Interest income | 2,327 | 2,825 |
| Interest expense | (667) | (25) |
| Other expense, net | (21) | (27) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s G&A?
- Kyverna Therapeutics, Inc. (KYTX) reported G&A of $11.29M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s G&A changed year-over-year?
- Kyverna Therapeutics, Inc.'s G&A increased by 13.2% year-over-year, from $9.98M to $11.29M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s G&A?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s G&A has grown at a 70.1% compound annual growth rate (CAGR), from $12.48M to $36.11M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Kyverna Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude